NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTX stock has increased by 53.9% and is now trading at $3.74. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aptinyx.

Aptinyx Inc (NASDAQ:APTX) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.01. The business earned $0.82 million during the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%. View Aptinyx's earnings history.

6 brokers have issued 12-month price targets for Aptinyx's stock. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's share price to reach $8.67 in the next year. This suggests a possible upside of 131.7% from the stock's current price. View analysts' price targets for Aptinyx.

News stories about APTX stock have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAptinyx.

Some companies that are related to Aptinyx include Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Radius Health (RDUS), Syndax Pharmaceuticals (SNDX) and Passage Bio (IMRA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (2.55%), Ikarian Capital LLC (1.30%), BlackRock Inc. (0.94%), Sphera Funds Management LTD. (0.90%), Geode Capital Management LLC (0.45%) and JPMorgan Chase & Co. (0.45%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View institutional ownership trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, and Squarepoint Ops LLC. View insider buying and selling activity for Aptinyx.

APTX stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ikarian Capital LLC, Sphera Funds Management LTD., Geode Capital Management LLC, Acadian Asset Management LLC, BlackRock Inc., JPMorgan Chase & Co., and Bank of New York Mellon Corp. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen. View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.74.

Aptinyx has a market capitalization of $170.77 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]